11/17
08:19 am
vtyx
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
Medium
Report
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
11/13
02:07 am
vtyx
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress [Yahoo! Finance]
Medium
Report
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress [Yahoo! Finance]
11/12
07:30 am
vtyx
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Medium
Report
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
11/11
01:23 pm
vtyx
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/8
11:37 am
vtyx
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock, down previously from $10.00.
Low
Report
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock, down previously from $10.00.
11/7
04:05 pm
vtyx
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Low
Report
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
10/15
01:32 pm
vtyx
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/15
08:00 am
vtyx
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Low
Report
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
9/23
02:05 pm
vtyx
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
9/23
08:00 am
vtyx
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Medium
Report
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
9/6
08:00 am
vtyx
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Neutral
Report
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
8/30
08:00 am
vtyx
Ventyx Biosciences Announces Departure of Chief Financial Officer
Low
Report
Ventyx Biosciences Announces Departure of Chief Financial Officer
8/28
08:00 am
vtyx
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Low
Report
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences